Activities of the semisynthetic glycopeptide LY191145 against vancomycin- resistant enterococci and other gram-positive bacteria

T. I. Nicas, D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, Robert Stratford Jr., R. D.G. Cooper

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin- resistant enterococci of ≤4 μg/ml for 50% of isolates and ≤16 μg/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 μg/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic- resistant gram-positive bacteria.

Original languageEnglish (US)
Pages (from-to)2585-2587
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Volume39
Issue number11
DOIs
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Glycopeptides
Gram-Positive Bacteria
Teicoplanin
chloroorienticin A
Anti-Bacterial Agents
Enterococcus
Vancomycin
Streptococcus
Staphylococcus
Infection
Vancomycin-Resistant Enterococci

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Activities of the semisynthetic glycopeptide LY191145 against vancomycin- resistant enterococci and other gram-positive bacteria. / Nicas, T. I.; Mullen, D. L.; Flokowitsch, J. E.; Preston, D. A.; Snyder, N. J.; Stratford Jr., Robert; Cooper, R. D.G.

In: Antimicrobial Agents and Chemotherapy, Vol. 39, No. 11, 01.01.1995, p. 2585-2587.

Research output: Contribution to journalArticle

Nicas, T. I. ; Mullen, D. L. ; Flokowitsch, J. E. ; Preston, D. A. ; Snyder, N. J. ; Stratford Jr., Robert ; Cooper, R. D.G. / Activities of the semisynthetic glycopeptide LY191145 against vancomycin- resistant enterococci and other gram-positive bacteria. In: Antimicrobial Agents and Chemotherapy. 1995 ; Vol. 39, No. 11. pp. 2585-2587.
@article{3b9f4edc6f5d474798890f4cf9b627d6,
title = "Activities of the semisynthetic glycopeptide LY191145 against vancomycin- resistant enterococci and other gram-positive bacteria",
abstract = "LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin- resistant enterococci of ≤4 μg/ml for 50{\%} of isolates and ≤16 μg/ml for 90{\%} of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 μg/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic- resistant gram-positive bacteria.",
author = "Nicas, {T. I.} and Mullen, {D. L.} and Flokowitsch, {J. E.} and Preston, {D. A.} and Snyder, {N. J.} and {Stratford Jr.}, Robert and Cooper, {R. D.G.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1128/AAC.39.11.2585",
language = "English (US)",
volume = "39",
pages = "2585--2587",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Activities of the semisynthetic glycopeptide LY191145 against vancomycin- resistant enterococci and other gram-positive bacteria

AU - Nicas, T. I.

AU - Mullen, D. L.

AU - Flokowitsch, J. E.

AU - Preston, D. A.

AU - Snyder, N. J.

AU - Stratford Jr., Robert

AU - Cooper, R. D.G.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin- resistant enterococci of ≤4 μg/ml for 50% of isolates and ≤16 μg/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 μg/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic- resistant gram-positive bacteria.

AB - LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin- resistant enterococci of ≤4 μg/ml for 50% of isolates and ≤16 μg/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 μg/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic- resistant gram-positive bacteria.

UR - http://www.scopus.com/inward/record.url?scp=0028828758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028828758&partnerID=8YFLogxK

U2 - 10.1128/AAC.39.11.2585

DO - 10.1128/AAC.39.11.2585

M3 - Article

C2 - 8585753

AN - SCOPUS:0028828758

VL - 39

SP - 2585

EP - 2587

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -